Aevi Genomic Medicine Signs an Option and License Agreement with AstraZeneca for its MEDI2338

Aevi Genomic Medicine Signs an Option and License Agreement with AstraZeneca for its MEDI2338

Shots:

  • AstraZeneca to receive option exercise fee in cash and equity, up to $162M as development & commercial milestones and royalties on global sales
  • Aevi Genomic to get an option to develop & commercialize AstraZeneca’s MEDI2338 and have to exercise the option within five mos. from the effective date of the agreement and will be responsible for clinical & commercial activities and costs. Exercising the option is contingent on Aevi securing additional funding
  • MEDI2338 is mAb targeting IL-18 and Aevi Genomics plans to initially develop MEDI2338 for adult onset Still’s disease (AOSD) and will further develop for other autoinflammatory disorders

Click here to­ read full press release/ article | Ref: Aevi Genomic Medicines | Image: Bloomberg